Panel Discussion: Investigating the Evolution of In Vivo Therapies to Accelerate Innovations

• Discussing the rapid progression of in vivo therapies, considering the impact on COGs and patient outcomes
• Highlighting in vivo innovations to develop more effective, scalable, and accessible therapies
• Evaluating what’s next for in vivo therapies to understand anticipated clinical progress, expanding disease indications and projected advancements for strategic planning

Speakers:

Ruth Salmon

Vice President, Preclinical Sciences

Bristol Myers Squibb

Luke Russell

Executive VP

Vyriad

Sidharth Kerkar

Founder & Chief Executive Officer

AllerGene AI